, Tracking Stock Market Picks
Enter Symbol:
TrovaGene, Inc. (TROV) [hlAlert]

up 21.94 %

TrovaGene, Inc. (TROV) rated Buy with price target $10 by Aegis Capital

Posted on: Wednesday,  Nov 13, 2013  9:25 AM ET by Aegis Capital

Aegis Capital rated Buy TrovaGene, Inc. (NASDAQ: TROV) on 11/13/2013. Previously Aegis Capital rated Buy TrovaGene, Inc. (NASDAQ: TROV) on 12/12/2012.,
when the stock price was $4.74. Since then, TrovaGene, Inc. has gained 21.94% as of 01/14/2016's recent price of $5.78.
If you would have followed the previous Aegis Capital's recommendation on TROV, you would have gained 21.94% of your investment in 1128 days.

TrovaGene, Inc. develops transrenal molecular diagnostics that addresses health problems. The company focuses on the development of tests using its patented transrenal nucleic acid technology (transrenal DNA/RNA molecular diagnostic technology). It intends to apply its proprietary transrenal DNA/RNA test platform to develop non-invasive molecular diagnostics. The company?s technology uses urine specimens and has a range of applications, including tumor detection and monitoring, infectious disease detection, prenatal testing, tissue transplantation, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. Its TrovaGene molecular diagnostics assays would provide information that will enable physicians to provide medical care for their patients. The company was formerly known as Xenomics, Inc. and changed its name to TrovaGene, Inc. on March 1, 2010. TrovaGene, Inc. was founded in 1999 and is headquartered in San Diego, California.

Aegis Capital
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/13/2013 9:25 AM Buy
5.70 10.00
as of 12/13/2013
1 Week down  -8.81 %
1 Month down  -8.97 %
3 Months down  -30.26 %
1 YTD down  -26.83 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/1/2013 10:25 AM Buy
8.06 14.00
4/1/2013 9:25 AM Buy
6.47 14.00
12/12/2012 8:25 AM Buy
4.74 12.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy